ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1812

Preeclampsia and Incident Cardiovascular Disease in SLE Pregnancy

Julia F Simard1, Marios Rossides2, Elizabeth V. Arkema3, Elisabet Svenungsson4, Anna-Karin Wikstrom5, Murray Mittleman6 and Jane E. Salmon7, 1Division of Epidemiology, Health Research and Policy Department, Stanford School of Medicine, Stanford, CA, 2Medicine Solna, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, 3Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 4Department of Medicine Solna, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, 5Clinical Epidemiology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden, 6Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, 7Medicine/Rheumatology, Hospital of Special Surgery, New York, NY

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Cardiovascular disease, pregnancy, registries and systemic lupus erythematosus (SLE), Reproductive Health

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Reproductive Issues in Rheumatic Disorders

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:

Pre-pregnancy cardiovascular health has been associated with preeclampsia during pregnancy, as well as future cardiovascular disease (CVD). Preeclampsia is related to endothelial dysfunction, hypertension, permanent vascular damage and increased arterial stiffness in the mother, factors associated with future CVD. It is unclear whether pregnancy unmasks endothelial vulnerability to injury which manifests as preeclampsia or whether the preeclampsia itself causes damage leading to CVD. Patients with SLE are at increased risk for preeclampsia as well as CVD and stroke. However, the relationship between these conditions has not been thoroughly examined among women with SLE.

Methods:

Using a population-based Swedish register linkage, we identified all singleton pregnancies in the Medical Birth Register (1987-2012) among mothers with prevalent SLE and a large general population comparator (non-SLE). SLE was defined as ³2 SLE ICD-coded visits (inpatient, outpatient non-primary care, or both) with at ³1 visit coded by specialist who manages SLE. Primary CVD outcomes included any recorded MI or stroke based on ICD10 codes in the Patient or Death Register. Power permitting, stroke and MI were considered separately. Multivariable-adjusted stratified Cox models estimated hazard ratios and 95% confidence intervals (HR, 95% CI) among all deliveries, using robust variance estimators to account for autocorrelation (multiple pregnancies), time-varying covariates, and calendar year as the stratification variable. Preeclampsia and maternal hypertensive disorders were time-varying, such that once a woman was exposed to a preeclampsia-complicated pregnancy, she remained exposed. Sensitivity analysis restricted to first births only. HRs and 95% CIs estimated the association between preeclampsia and CVD in SLE vs non-SLE. We calculated the relative excess risk due to interaction (RERI) to assess for non-additivity.

Results:

Among 1207 SLE pregnancies, 19.4% were preeclampsia-exposed compared to 6.9% of the 18784 non-SLE pregnancies. SLE mothers were more likely to have pregestational hypertension and diabetes, renal disease, and DVT/pulmonary embolism. Among women with SLE, these pregestational comorbidities were more common in those with preeclampsia (renal disease history in 37% vs. 9% among normotensives). Any preeclampsia was associated with a 2.7-fold increased rate of CVD in both women with SLE and from the general population (RERI=18.8 (-5.3 to 42.9)). We found a significant interaction on the additive scale for stroke as the outcome (RERI=35.2 (1.1, 69.5); preeclampsia was associated with a roughly 4.5-fold increased rate of stroke in SLE but not associated with stroke in non-SLE.

Conclusion:

We confirmed that women with preeclampsia are at increased risk of future CVD, regardless of whether they had SLE during pregnancy or not. There was an excess risk of stroke specifically among women with SLE when compared to women from the general population.


Disclosure: J. F. Simard, None; M. Rossides, None; E. V. Arkema, None; E. Svenungsson, None; A. K. Wikstrom, None; M. Mittleman, None; J. E. Salmon, None.

To cite this abstract in AMA style:

Simard JF, Rossides M, Arkema EV, Svenungsson E, Wikstrom AK, Mittleman M, Salmon JE. Preeclampsia and Incident Cardiovascular Disease in SLE Pregnancy [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/preeclampsia-and-incident-cardiovascular-disease-in-sle-pregnancy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/preeclampsia-and-incident-cardiovascular-disease-in-sle-pregnancy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology